The findings presented here suggest that a subset of HER2− breast cancer patients whose cells display abnormal HER2 signaling activity as measured by the CELx HSP test may be candidates for HER2 signaling inhibitors. This evidence concerns the gene ERBB2 and breast carcinoma.